Getinge AB

  • Market Cap: Mid Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: SE0000202624
SEK
187.00
2.2 (1.19%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

52 Week

Valuation
Technical
Day's Volume

CASH

327.9 k

Shareholding (Jun 2020)

FII

0.32%

Held by 1 FIIs

DII

99.68%

Held by 0 DIIs

Promoter

0.00%

iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

Dashboard

1

Positive results in Dec 25

  • DIVIDEND PER SHARE(HY) Highest at SEK 4.38
  • RAW MATERIAL COST(Y) Fallen by -4.18% (YoY)
  • INVENTORY TURNOVER RATIO(HY) Highest at 3.09 times
2

With ROE of 7.77%, it has a expensive valuation with a 1.97 Price to Book Value

3

Company is among the highest 1% of companies rated by MarketsMojo across all 4,000 stocks

 
stock-summaryMojo Parameters

Mojo Parameters

Stock DNA

stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

SEK 51,464 Million (Mid Cap)

stock-summary
P/E

25.00

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

2.27%

stock-summary
Debt Equity

0.22

stock-summary
Return on Equity

8.70%

stock-summary
Price to Book

1.75

Revenue and Profits:
Net Sales:
10,186 Million
(Quarterly Results - Dec 2025)
Net Profit:
869 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-12.33%
0%
-12.33%
6 Months
-7.2%
0%
-7.2%
1 Year
-15.46%
0%
-15.46%
2 Years
-11.12%
0%
-11.12%
3 Years
-22.89%
0%
-22.89%
4 Years
-47.72%
0%
-47.72%
5 Years
-22.25%
0%
-22.25%

Getinge AB for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions

News

Icon
No Recent News for the Company

Announcements stock-summary

Icon
No announcement available

Corporate Actions stock-summary

Icon
No corporate action available
stock-summaryKey Factors

Quality key factors stock-summary

Factor
Value
Sales Growth (5y)
3.24%
EBIT Growth (5y)
-2.85%
EBIT to Interest (avg)
17.04
Debt to EBITDA (avg)
0.36
Net Debt to Equity (avg)
0.20
Sales to Capital Employed (avg)
0.86
Tax Ratio
27.86%
Dividend Payout Ratio
57.30%
Pledged Shares
0
Institutional Holding
0.32%
ROCE (avg)
15.39%
ROE (avg)
10.58%

Valuation key factors

Factor
Value
P/E Ratio
25
Industry P/E
Price to Book Value
1.97
EV to EBIT
14.59
EV to EBITDA
9.77
EV to Capital Employed
1.75
EV to Sales
1.83
PEG Ratio
NA
Dividend Yield
2.06%
ROCE (Latest)
12.02%
ROE (Latest)
7.77%

Technicals key factors

Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bearish
Bearish
Moving Averages
Bearish (Daily)
KST
Bearish
Bullish
Dow Theory
Mildly Bearish
Mildly Bearish
OBV
No Trend
Mildly Bearish
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Jun 2020stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Foreign Institutions

Domestic Funds

Held in 0 Schemes (0%)

Foreign Institutions

Held by 1 Foreign Institutions (0.32%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Dec'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Dec 2025 is -7.99% vs 11.79% in Dec 2024",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Dec 2025 is 30.09% vs -7.09% in Dec 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Dec'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "10,186.00",
          "val2": "11,071.00",
          "chgp": "-7.99%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "2,104.00",
          "val2": "2,259.00",
          "chgp": "-6.86%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "164.00",
          "val2": "173.00",
          "chgp": "-5.20%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "-39.00",
          "val2": "-622.00",
          "chgp": "93.73%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "869.00",
          "val2": "668.00",
          "chgp": "30.09%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "153.40%",
          "val2": "148.90%",
          "chgp": "0.45%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2025 is 0.60% vs 9.21% in Dec 2024",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2025 is 37.61% vs -31.88% in Dec 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Dec'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "34,969.00",
          "val2": "34,759.00",
          "chgp": "0.60%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "6,628.00",
          "val2": "6,187.00",
          "chgp": "7.13%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "644.00",
          "val2": "500.00",
          "chgp": "28.80%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "-398.00",
          "val2": "-1,717.00",
          "chgp": "76.82%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "2,276.00",
          "val2": "1,654.00",
          "chgp": "37.61%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "130.50%",
          "val2": "117.60%",
          "chgp": "1.29%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Dec'25 - YoYstock-summary

Dec'25
Dec'24
Change(%)
Net Sales
10,186.00
11,071.00
-7.99%
Operating Profit (PBDIT) excl Other Income
2,104.00
2,259.00
-6.86%
Interest
164.00
173.00
-5.20%
Exceptional Items
-39.00
-622.00
93.73%
Consolidate Net Profit
869.00
668.00
30.09%
Operating Profit Margin (Excl OI)
153.40%
148.90%
0.45%
USD in Million.
Direction Arrows
Net Sales

YoY Growth in quarter ended Dec 2025 is -7.99% vs 11.79% in Dec 2024

Direction Arrows
Consolidated Net Profit

YoY Growth in quarter ended Dec 2025 is 30.09% vs -7.09% in Dec 2024

Annual Results Snapshot (Consolidated) - Dec'25stock-summary

Dec'25
Dec'24
Change(%)
Net Sales
34,969.00
34,759.00
0.60%
Operating Profit (PBDIT) excl Other Income
6,628.00
6,187.00
7.13%
Interest
644.00
500.00
28.80%
Exceptional Items
-398.00
-1,717.00
76.82%
Consolidate Net Profit
2,276.00
1,654.00
37.61%
Operating Profit Margin (Excl OI)
130.50%
117.60%
1.29%
USD in Million.
Direction Arrows
Net Sales

YoY Growth in year ended Dec 2025 is 0.60% vs 9.21% in Dec 2024

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2025 is 37.61% vs -31.88% in Dec 2024

stock-summaryCompany CV
About Getinge AB stock-summary
stock-summary
Getinge AB
Pharmaceuticals & Biotechnology
Getinge AB is a Sweden-based company active in the healthcare sector. It provides products and services for intensive care units, sterilization centers, elderly care and companies and institutions active in the life sciences area. Its operations are divided into three business areas: The Medical Systems business area offers equipment for surgical disciplines, cardiology and intensive care; the Extended Care business area offers products and services geared toward the hospital and elderly care markets, including solutions for preventing the risk of pressure ulcers and deep vein thrombosis, and the Infection Control business area features systems for preventing the occurrence and spread of infection. Its products comprise disinfectors, sterilizers, including low temperature sterilization solutions, information technology (IT) solutions, as well as advice, training and technical support. The Company's products are sold under the Getinge, Lancer, ArjoHuntleigh and MAQUET brands.
Company Coordinates stock-summary
Company Details
Ekebergsvagen 26,, P.O. Box 69 GOETEBORG None : 305 75
stock-summary
Tel: 46 3 515550046 10 3350043
stock-summary
Registrar Details